knowledge -WSS

knowledge

author：fashion 2025-09-01 15:10:04 - browse：5737

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： FDA warns medical device makers about rise in fabricated data

WSS

Researchers tackle phage therapy hurdles for wider adoption

Obamacare plans could cover weight loss drugs

Obamacare plans could cover weight loss drugs

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

The FDA weighs the risks of candy

Surprise medical billing ban raises prices elsewhere

knowledge

knowledge

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Obamacare plans could cover weight loss drugs

Dobbs anniversary: the lost opportunity of abortion as health care

FDA warns medical device makers about rise in fabricated data

United colonoscopy coverage change 'may cost lives,' doctors say

Telehealth options flood the market as retailers push virtual care

In age of alternative facts, a scholarly course on calling out crap

New study raises questions about niacin and heart health

Drug repurposing or repositioning? The language matters

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

knowledge

Hospitals are piloting generative AI tools as regulators play catch

Hospitals warn Medicare's drug payment fix is ‘unlawful’

MD Anderson's Padmanee Sharma responds to research credit suit

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

The FDA weighs the risks of candy

entertainment

knowledge

hotspot

leisure time